I'll touch on a few things. One is something like looking at commercialization, I think that was the right way to go, $100 million; show me you're going to commercialize in three years and we'll invest. That was a great program, and we'll see how that plays out.
The other thing is that we need to get rid of some redundancies. There is redundancy in the system if you look at the regulatory front. We need to speed up regulatory approval so that's clarified—